Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Preview report featuring updated forecasts for the biopharma market for 2025.

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Counterfeit versions of Wegovy or Zepbound are different from compounded weight loss drugs. Compounding is a legitimate practice that’s monitored by the Food and Drug Administration. Compounded ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...